| 摘要 |
PROBLEM TO BE SOLVED: To provide an ibandronate crystal polymorphism A which is a pharmaceutically active compound which acts as an efficient bone anti-resorptive drug that directly inhibits osteoclasts activity and also increases bone mass, and which can be used for the treatment and/or prevention of diseases which are associated with bone and calcium metabolic diseases such as, for instance, osteoporosis or Paget's disease.SOLUTION: The present invention relates to a novel polymorph crystal form of 3-(N-methyl-N'-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (ibandronate) expressed by the following formula (I). An ibandronate polymorph has characteristic peaks expressed in Figure 3. |
